Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Has Average Target Price of $42.75

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $42.75.

Separately, Weiss Ratings lowered shares of Kailera Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th.

Hedge Funds Weigh In On Kailera Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics in the 2nd quarter valued at about $24,233,000. State Street Corp acquired a new stake in shares of Kailera Therapeutics during the second quarter valued at about $19,126,000. Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Kailera Therapeutics during the second quarter valued at about $113,923,000. Wellington Management Group LLP purchased a new stake in shares of Kailera Therapeutics during the second quarter worth about $64,308,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Kailera Therapeutics during the second quarter worth about $993,000.

Kailera Therapeutics Price Performance

Shares of NASDAQ:KLRA opened at $11.61 on Friday. The firm has a market capitalization of $1.51 billion and a P/E ratio of -0.00. The firm has a 50 day moving average price of $15.03. Kailera Therapeutics has a 52-week low of $9.76 and a 52-week high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA) last posted its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). On average, equities research analysts anticipate that Kailera Therapeutics will post -3.89 EPS for the current year.

Kailera Therapeutics Company Profile

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.